Search Results - "Halker Singh, Rashmi B."

Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.

Authors: Lipton, Richard B. Halker Singh, Rashmi B. Mechtler, Laszlo et al.

Source: Cephalalgia. Sep2023, Vol. 43 Issue 9, p1-10. 10p.

Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.

Authors: Tassorelli, Cristina Onishchenko, Kateryna Halker Singh, Rashmi B. et al.

Source: Cephalalgia. Feb2024, Vol. 44 Issue 2, p1-11. 11p.

Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene–related peptide monoclonal antibodies.

Authors: Ailani, Jessica Lalla, Anjana Halker Singh, Rashmi B et al.

Source: Cephalalgia. Nov2024, Vol. 44 Issue 11, p1-11. 11p.

Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials.

Authors: Halker Singh, Rashmi B. Aycardi, Ernesto Bigal, Marcelo E. et al.

Source: Cephalalgia. Jan2019, Vol. 39 Issue 1, p52-60. 9p. 2 Charts, 2 Graphs.

Harassment in the headache field: a global web-based cross-sectional survey.

Authors: de Boer, Irene Ambrosini, Anna Halker Singh, Rashmi B. et al.

Source: Cephalalgia. Aug2023, Vol. 43 Issue 8, p1-12. 12p.

Abstracts from the 22 nd International Headache Congress, 11-13 September 2025, São Paulo, Brazil.

Source: Cephalalgia. 2025 Suppl 1, Vol. 45, p1-455. 455p.

Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update.

Authors: Charles, Andrew C. Digre, Kathleen B. Goadsby, Peter J. et al.

Source: Headache: The Journal of Head & Face Pain. Apr2024, Vol. 64 Issue 4, p333-341.

Perceived barriers to career progression in the headache field: A global web-based cross-sectional survey.

Authors: de Boer, Irene Ambrosini, Anna Halker Singh, Rashmi B et al.

Source: Cephalalgia. Dec2022, Vol. 42 Issue 14, p1498-1509. 12p.

Headache fellowship match shareholder insights.

Authors: Kanegi, Skyler L. Zhang, Niushen Armand, Cynthia E. et al.

Source: Headache: The Journal of Head & Face Pain. Jun2022, Vol. 62 Issue 6, p766-769. 4p.

Subjects: Hospital medical staff, Medical students, Attitudes of medical personnel, Information resources, Headache, Medical fellowships, Student attitudes, Medical education, World Wide Web

Geographic Terms: United States

Ten Eleven Things Not to Say to Healthcare Professionals During the Coronavirus Disease 2019 Pandemic.

Authors: Robblee, Jennifer Buse, Dawn C. Halker Singh, Rashmi B. et al.

Source: Headache: The Journal of Head & Face Pain. Sep2020, Vol. 60 Issue 8, p1837-1845.

A qualitative evidence synthesis of patient perspectives on migraine treatment features and outcomes.

Authors: Urtecho, Meritxell Wagner, Brittin Wang, Zhen et al.

Source: Headache: The Journal of Head & Face Pain. Feb2023, Vol. 63 Issue 2, p185-201.

Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing‐off of erenumab within monthly treatment cycle.

Authors: Dodick, David W. Blumenfeld, Andrew M. Halker Singh, Rashmi B. et al.

Source: Headache: The Journal of Head & Face Pain. Feb2023, Vol. 63 Issue 2, p233-242.

Worsening migraine: Another casualty of natural disasters.

Authors: Gelfand, Amy A. Halker Singh, Rashmi B. Robbins, Matthew S.

Source: Headache: The Journal of Head & Face Pain. Jun2022, Vol. 62 Issue 6, p645-647. 3p.

Subjects: Rural health services, Migraine, Natural disasters, Psychological stress

Geographic Terms: Japan

Advancing our commitment to our peer reviewers.

Authors: Halker Singh, Rashmi B. Bobker, Sarah M. Roberts, Jason L. et al.

Source: Headache: The Journal of Head & Face Pain. Oct2021, Vol. 61 Issue 9, p1299-1301. 3p.

Subjects: Professional peer review, Occupational achievement, Manuscripts, Serial publications, Organizational change, Commitment (Psychology), COVID-19 pandemic, Corporate culture

Narrative review of neuroimaging in migraine with aura.

Authors: Arca, Karissa N. VanderPluym, Juliana H. Halker Singh, Rashmi B.

Source: Headache: The Journal of Head & Face Pain. Oct2021, Vol. 61 Issue 9, p1324-1333.

Grand rounds education in neurology, with a focus on headache medicine.

Authors: Burish, Mark J. Ahmed, Zubair A. Rosen, Noah L. et al.

Source: Headache: The Journal of Head & Face Pain. Jul2021, Vol. 61 Issue 7, p1077-1085.

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study.

Authors: Lipton, Richard B. Cohen, Joshua M. Bibeau, Kristen et al.

Source: Headache: The Journal of Head & Face Pain. Nov2020, Vol. 60 Issue 10, p2444-2453.

COVID‐19 and Headache Medicine: A Narrative Review of Non‐Steroidal Anti‐Inflammatory Drug (NSAID) and Corticosteroid Use.

Authors: Arca, Karissa N. Smith, Jonathan H. Chiang, Chia‐Chun et al.

Source: Headache: The Journal of Head & Face Pain. Sep2020, Vol. 60 Issue 8, p1558-1568.

Migraine Care in the Era of COVID‐19: Clinical Pearls and Plea to Insurers.

Authors: Szperka, Christina L. Ailani, Jessica Barmherzig, Rebecca et al.

Source: Headache: The Journal of Head & Face Pain. May2020, Vol. 60 Issue 5, p833-842.

Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II.

Authors: Dodick, David W. Lipton, Richard B. Ailani, Jessica et al.

Source: Headache: The Journal of Head & Face Pain. Apr2020, Vol. 60 Issue 4, p686-700.